AKESO Aktie

 

HONG KONG, July 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (ADC), AK146D1,......

HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen......

HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented as an oral presentation at the 2026......

HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy......

The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Study results showed that gumokimab delivered rapid and strong efficacy. The post China's NMPA approves Akeso's gumokimab for plaque psoriasis appeared first on Pharmaceutical Business review....

AKESO (09926.HK) announced that Qiyoukang (gumoqi monoclonal antibody, AK111) has been approved for marketing by the National Medical Products Administration (NMPA) of China for the treatment of moderate-to-severe plaque psoriasis.The approval of gumoqi monoclonal antibody for moderate-to-severe plaque psoriasis is based on one ......

HONG KONG, June 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with......

There was HKD950.8 million, HKD344.4 million and HKD32 million Southbound Trading net inflow to SMIC (00981.HK), AKESO (09926.HK) and BABA-W (09988.HK).There was HKD2.1 billion, HKD916.6 million and HKD716.4 million Southbound Trading net outflow from TENCENT (00700.HK), XIAOMI-W (01810.HK) and MEITUAN-W (03690.HK).For Southboun......

BofAS issued a report stating that AKESO (09926.HK) presented the overall survival analysis of the HARMONi-6 study at the oral Plenary Session of ASCO 2026. This marks the first time in ASCOs 61-year history that an innovative oncology drug originally developed in China has been selected for the Plenary Session.Given the strong ......

Akeso, whose drug ivonescimab was hailed as biotech's “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses. Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and have revised their target prices upwards. The drug's phase three trial found that ivonescimab reduced the risk of death......

There was HKD2.7 billion, HKD1 billion and HKD800.9 million Southbound Trading net inflow to AKESO (09926.HK), TENCENT (00700.HK) and POP MART (09992.HK).There was HKD547.5 million, HKD208.3 million and HKD200.4 million Southbound Trading net outflow from LENOVO GROUP (00992.HK), KB LAMINATES (01888.HK) and HUA HONG SEMI (01347.......

Akeso CFO Bing Wang says the Chinese biotech firm is investing “significantly” to expand manufacturing of its lung cancer drug as it anticipates growing demand in China and the US. He speaks exclusively to Bloomberg after Akeso presented positive results for the drug at the American Society of Clinical Oncology's annual meeting. (Source: Bloomberg)...

AKESO (09926.HK) announced the results of its HARMONI-6 clinical trial. Extending last Fri (29th)'s rally, the stock opened 9.23% higher today (1st) and once surged 12.3% to a peak of HKD132.6 in early trading. Gains later narrowed, and it is now trading at HKD124.1, up 5.08%, with turnover surging to 31.5814 million shares, inv......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

AKESO (09926.HK) announced that more than 40 clinical research findings related to its self-developed innovative drugs were officially presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The results mainly focused on the companys globally first-in-class bispecific antibody core product cadonilimab ......

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a......

A lung cancer drug developed by Akeso Inc. extended patients' lives by about four months in a late-stage trial in China, results that will likely raise expectations for a closely watched new class of treatments....

HONG KONG, May 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2 in......